您好,欢迎来到试剂仪器网! [登录] [免费注册]
试剂仪器网
位置:首页 > 产品库 > Vildagliptin-d7
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Vildagliptin-d7
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Vildagliptin-d7图片
CAS NO:1133208-42-0
包装与价格:
包装价格(元)
500 μg电议
1mg电议

产品介绍
An internal standard for the quantification of vildagliptin
Cas No.1133208-42-0
别名维格列汀D7,LAF237-d7; NVP-LAF 237-d7
Canonical SMILESO=C(CN[C@@]1(CC(C2)C3)CC3C[C@]2(O)C1)N4[C@]([2H])(C#N)C([2H])([2H])C([2H])([2H])C4([2H])[2H]
分子式C17H18D7N3O2
分子量310.4
溶解度DMF: 20 mg/ml,DMSO: 15 mg/ml,Ethanol: 15 mg/ml,PBS (pH 7.2): 10 mg/ml
储存条件Store at -20°C
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping ConditionEvaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
产品描述

Vildagliptin-d7has 7 deuteriums. Vildagliptin-d7is intended for use as an internal standard for the quantification of vildagliptin by GC- or LC-MS. Vildagliptin is an inhibitor of DPP-4 (IC50= 3.5-34 nM).1,2It also inhibits DPP-8 and DPP-9 (Ki= 810 and 95 nM, respectively) but not DPP-2 or the related fibroblast activation protein α.3Through its effects on DPP-4, it blocks the degradation of several circulating peptides, including incretins (stimulators of insulin secretion) like glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1.4,5Vildagliptin reduces fasting and postprandial glucose levels and decreases inflammatory and oxidative stress in diverse animal models of disease.6,7

1.Weber, A.E.Dipeptidyl peptidase IV inhibitors for the treatment of diabetesJournal of Medicinal Chemistry47(17)4135-4141(2004) 2.Parmee, E.R., He, J., Mastracchio, A., et al.4-amino cyclohexylglycine analogues as potent dipeptidyl peptidase IV inhibitorsBioorganic & Medicinal Chemistry Letters14(1)43-46(2004) 3.Ikuma, Y., Hochigai, H., Kimura, H., et al.Discovery of 3H-imidazol[4,5-c]quinolin-4(5H)-ones as potent and selective dipeptidyl peptidase IV (DPP-4) inhibitorsBioorganic & Medicinal Chemistry20(19)5864-5883(2012) 4.Mari, A., Sallas, W.M., He, Y.L., et al.Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed β-cell function in patients with type 2 diabetesJournal of Clinical Endocrinology and Metabolism90(8)4888-4894(2005) 5.Burkey, B.F., Li, X., Bolognese, L., et al.Acute and chronic effects of the incretin enhancer vildagliptin in insulin-resistant ratsJournal of Pharmacology and Experimental Therapeutics315(2)688-695(2005) 6.Scheen, A.J.Cardiovascular effects of gliptinsNat.Rev.Cardiol.10(2)73-84(2013) 7.Strain, W.D., Lukashevich, V., Kothny, W., et al.Individualised treatment targets for elderly patients with type 2 diabetes using vildagliptin add-on or lone therapy (INTERVAL): A 24 week, randomised, double-blind, placebo-controlled studyLangmuir382(9890)409-416(2013)